Newer antidepressants for hot flashes

Contemporary Ob-Gyn

Volumn 46, Issue 11, 2001, Pages 61-70

  Loprinzi, Charles L ^a,b,c   Barton, Debra L ^d,e   Rhodes, Deborah J ^a,d   Wahner Roedler, Dietlind L ^a,d  

^a MAYO CLINIC COLLEGE OF MEDICINE   (United States)

^b Eli Lilly ^*  (United States)

^c BRISTOL MYERS SQUIBB   (United States)

^d MAYO CLINIC   (United States)

^e GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 10444255518     PISSN: 00903159     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Eskin BA. The Menopause: Comprehensive Management. New York, NY: McGraw-Hill. Health Professions Division; 1994:14.
2. Greendale GA, Lee NP, Arriola ER. The menopause. Lancet. 1999;353:571-580.
3. Steingold KA, Laufer L, Chetkowski RJ, et al. Treatment of hot flashes with transdermal estradiol administration. J Clin Endocrinol Metab. 1985;61:627-632.
4. Greendale GA, Reboussin BA, Hogat P, et al. Symptom relief and side effects of postmenopausal hormones: results from the Postmenopausal Estrogen/Progestin Interventions Trial. Obstet Gynecol. 1998;92:982-988.
5. Lobo RA, McCormick W, Singer F, et al. Depo-medroxy-progesterone acetate compared with conjugated estrogens for the treatment of postmenopausal women. Obstet Gynecol. 1984;63:1-5.
6. Loprinzi CL, Michalak JC, Quella SK, et al. Megestrol acetate for the prevention of hot flashes. N Engl J Med. 1994;331:347-352.
7. Treatment of estrogen deficiency symptoms in women surviving breast cancer. Part 6: Executive summary and consensus statement. Proceedings of a conference held at Boar's Head Inn, Charlottesville, Virginia, September 21-23, 1997. Oncology (Huntingt). 1999;13:859-861, 865-866, 871, 872 passim.
8. Key TJ, Pike MC. The role of oestrogens and progestagens in the epidemiology and prevention of breast cancer, Eur J Cancer Clin Oncol. 1988;24:29-43.
9. Lauver DR, Settersten L, Marten S, et al. Explaining women's intentions and use of hormones with menopause. Res Nurs Health. 1999;22:309-320.
10. Castelo-Branco C, Figueras F, Sanjuan A, et al. Long-term compliance with estrogen replacement therapy in surgical post menopausal women: benefits to bone and analysis of factors associated with discontinuation. Menopause. 1999;6:307-311.
11. Vassiloupoulou-Sellin R, Asmar L, Hortobagyi GN, et al. Estrogen replacement therapy after localized breast cancer: clinical outcome of 319 women followed prospectively. J Clin Oncol. 1999;17:1482-1487.
12. Eden JA, Bush T, Nand S, et al. A case-control study of combined continuous estrogen-progestin replacement therapy among women with a personal history of breast cancer. Menopause. 1995;2:67-72.
13. Sellars TA, Mink PJ, Cerhan JR, et al. The role of hormone replacement therapy in the risk for breast cancer and total mortality in women with a family history of breast cancer. Ann Intern Med. 1997;127:973-980.
14. Byrne C, Connolly JL, Colditz GA, et al. Biopsy confirmed benign breast disease, postmenopausal use of exogenous female hormones, and breast carcinoma risk. Cancer. 2000;89:2046-2052.
15. Dupont WD, Page DL, Parl FF, et al. Estrogen replacement therapy in women with a history of proliferative breast disease. Cancer. 1999;85:1277-1283.
16. Goldberg RM, Loprinzi CL, O'Fallon JR, et al. Transdermal clonidine for ameliorating tamoxifen-induced hot flashes. J Clin Oncol. 1994;12;155-158.
17. Hammond MG, Hatley L, Talbert LM. A double-blind study to evaluate the effect of methyldopa on menopausal vasomotor flushes. J Clin Endocrinol Metab. 1984;58:1158-1160.
18. Barton DL, Loprinzi CL, Quella SK, et al. Prospective evaluation of vitamin E for hot flashes in breast cancer survivors. J Clin Oncol. 1998;16:495-500.
19. Bergmans MG, Merkus JM, Corbey RS, et al. Effect of Bellergal Retard on climacteric complaints: a double-blind, placebo-controlled study. Maturitas. 1987;9:227-234.
20. Loprinzi CL, Pisansky TM, Fonseca R, et al. Pilot evaluation of venlafaxine hydrochloride for the therapy of hot flashes in cancer survivors. J Clin Oncol. 1998;16:2377-2381.
21. Stearns V, Isaacs C, Rowland J, et al. A pilot trial assessing the efficacy of paroxetine hydrochloride (Paxil) in controlling hot flashes in breast cancer survivors. Ann Oncol. 2000;11:17-22.
22. Loprinzi CL, Kugler JW, Sloan JA, et al. Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial. Lancet. 2000;356:2059-2063.
23. Beck AT, Steer RA, Garbin MG. Psychometric properties of the Beck Depression Inventory; 25 years of evaluation. Clin Psychol Rev. 1988;8:77-100.
24. Barton D, LaVasseur B, Loprinzi C, et al. Venlafaxine for the control of hot flashes: results of a longitudinal continuation study. Oncol Nurs Forum. (in press).
25. Loprinzi C, Sloan J, Perez E, Quella S, Stella P, et al. Phase III evaluation of fluoxetine (Prozac) for treatment of hot flashes. (In preparation).
26. Kimmick GG, Lovato J, McQuellon R, et al. Randomized, placebo-controlled study of sertraline (Zoloft™) for the treatment of hot flashes in women with early stage breast cancer taking tamoxifen. Proc ASCO. 2001;20(1):397a, abstract 1585.
27. Endicott J. History, evolution, and diagnosis of premenstrual dysphoric disorder. J Clin Psychiatry. 2000:61 (suppl 12):5-8.
28. Keller MB. The long-term treatment of depression. J Clin Psychiatry. 1999:60(suppl 17):41-45.
29. Jermain DM, Preece CK, Sykes RL, et al. Luteal phase sertraline treatment for premenstrual dysphoric disorder: results of a double-blind, placebo-controlled, crossover study. Arch Fam Med. 1999;8:328-332.
30. Romano S, Judge R, Dillon J, et al. The role of fluoxetine in the treatment of premenstrual dysphoric disorder. Clin Ther. 1999;21:615-629.
31. Freedman RR. Biochemical, metabolic, and vascular mechanisms in menopausal hot flashes. Fertil Steril. 1998;70:332-337:1998.
32. Kronenberg F. Hot flashes: epidemiology and physiology. Ann NY Acad Sci. 1990;592:55-86.
33. Schow DA, Renfer LG, Rozanski TA, et al. Prevalence of hot flushes during and after neoadjuvant hormonal therapy for localized prostate cancer. South Med J. 1998;91: 855-857.
34. Quella S, Loprinzi CL, Dose AM. A qualitative approach to defining "hot flashes" in men. Urol Nurs. 1994;14: 155-158.
35. Roth AJ, Scher HI. Sertraline relieves hot flashes secondary to medical castration as treatment of advanced prostate cancer. Psychooncology. 1998;7:129-132.
36. Guttuso TJ Jr. Gabapentin's effects on hot flashes and hypothermia. Neurology. 2000;54:2161-2163.